Patents Examined by Christopher Yaen
-
Patent number: 7326529Abstract: The present invention provides new markers and methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer.Type: GrantFiled: May 8, 2003Date of Patent: February 5, 2008Assignee: diaDexus, Inc.Inventors: Shujath Ali, Robert Cafferkey, Herve Recipon, Yongming Sun
-
Patent number: 7323168Abstract: Immunotherapy utilizing naked anti-granulocyte antibodies provides an effective means for treating chronic myelocytic leukemia (CML). Such antibodies can be administered alone or in combination with other therapies, such as immunoconjugates or chemotherapeutics. In either format, an effective therapy for treating CML is provided, which avoids the toxic side-effects typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating acute myelocytic leukemia (AML) when co-administered with inducing agents which induce expression of antigens minimally displayed on the surface of myeloblasts.Type: GrantFiled: May 26, 2004Date of Patent: January 29, 2008Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen
-
Patent number: 7317077Abstract: The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein.Type: GrantFiled: November 15, 2002Date of Patent: January 8, 2008Assignee: Nymox Pharmaceutical CorporationInventors: Paul Averback, Jack Gemmell
-
Patent number: 7303911Abstract: An increasingly aged population and better diagnosis has lead to an apparent increase in the prevalence of prostate cancer in men. There is an acute need to better understand the progression of this disease from its locally confined site of initiation to the end stage widely metastatic disease with attendant morbidity and mortality, It has historically been difficult to raise and maintain immortalized prostate cell lines in culture. We have derived a cell line selected from the group consisting of clones ONYCAP 1 and ONYCAP23. The cell lines are characterized as being prostate epithelial in origin.Type: GrantFiled: March 30, 2001Date of Patent: December 4, 2007Assignee: Onyvax LimitedInventors: Peter Thraves, Andrew Sutton
-
Patent number: 7264820Abstract: This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-?, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen.Type: GrantFiled: June 5, 2001Date of Patent: September 4, 2007Assignee: The Regents of the University of CaliforniaInventors: John C. Hiserodt, Martin R. Graf, Gale A. Granger
-
Patent number: 7176289Abstract: A method of modulating angiogenesis in a vertebrate subject, the method comprising administering to the vertebrate subject an ECRTP/DEP-1 activity-modulating amount of a composition, whereby an ECRTP/DEP-1 within the vertebrate subject is contacted by the composition; and modulating angiogenesis through the contacting of the ECRTP/DEP-1 with the composition. Optionally, the composition includes a monoclonal antibody which preferentially binds ECRTP/DEP-1. Methods for screening for modulators of ECRTP/DEP-1 are also disclosed.Type: GrantFiled: March 1, 2000Date of Patent: February 13, 2007Assignee: Vanderbilt UniversityInventors: Thomas O. Daniel, Takamune Takahashi, Raymond Mernaugh
-
Patent number: 7135177Abstract: The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab' domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells.Type: GrantFiled: February 28, 2001Date of Patent: November 14, 2006Assignee: The Regents of the University of CaliforniaInventors: Christopher C. Benz, Demetrois Papahadjopoulos, John W. Park, Keelung Hong, Dmitri Kirpotin
-
Patent number: 7115722Abstract: The present invention relates to monoclonal antibody H11 and antigen binding fragments that specifically bind to the antigen recognized by H11, the C-antigen. The C-antigen is found specifically on neoplastic cells and not on normal cells. Also disclosed are polynucleotide and polypeptide derivatives based on H11, including single chain V region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the H11 antibody is effective in diagnosing, localizing, and/or treating neoplasias. The invention further provides methods for treating a neoplastic disease, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell lung carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a composition of this invention in hopes of reducing the risk of recurrence. Patients may also be treated concurrently with the antibodies and traditional anti-neoplastic agents.Type: GrantFiled: May 22, 1997Date of Patent: October 3, 2006Assignee: Viventia Biotech, Inc.Inventors: Michael D. Dan, Howard A. Kaplan, Pradip K. Maiti
-
Patent number: 7115265Abstract: ABCC3, GPNMB, NNMT, and SEC61? are expressed at higher levels in glioblastoma than in normal brain tissue. These four genes and their expression products are useful for diagnosing and treating glioblastoma and for identifying potential anticancer drugs.Type: GrantFiled: May 14, 2001Date of Patent: October 3, 2006Assignee: Duke UniversityInventors: Gregory J. Riggins, Anita Lal, William T. Loging
-
Patent number: 7081522Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.Type: GrantFiled: January 19, 2000Date of Patent: July 25, 2006Assignee: Agene Research Institute Co., Ltd.Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
-
Patent number: 7074613Abstract: The invention concerns a hybridome called 5C5 (CNCM no I-2184) and the monoclonal antibody 5C5 which it produces. Said monoclonal antibody which specifically recognises most human renal cell carcinomas, is developed for diagnosing, imaging and treating human renal cell carcinomas.Type: GrantFiled: May 10, 2000Date of Patent: July 11, 2006Assignee: Centre National de la Rechershe ScientifiqueInventors: François Hirsch, Eric Angevin
-
Patent number: 7030212Abstract: A tumor antigen that comprises, as an active ingredient, a product of the Wilms', tumor suppressor gene WT1 or a peptide composed of 7–30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.Type: GrantFiled: July 30, 1999Date of Patent: April 18, 2006Assignee: Haruo SugiyamaInventors: Haruo Sugiyama, Yoshihiro Oka
-
Patent number: 7026454Abstract: The present invention involves a novel neuroendocrine growth factor or marker (“NEM”) identified in cultured prostate cancer cells and conjugates of NEM and a binding agent capable of inhibiting binding of NEM to its receptor.Type: GrantFiled: February 16, 1999Date of Patent: April 11, 2006Assignee: University of Kansas Medical CenterInventor: Girish V. Shah
-
Patent number: 6897054Abstract: This application provides human H37 protein having an amino acid sequence of SEQ ID NO: 1 or NO: 2; human gene encoding the protein; cDNA of the human gene which has a base sequence of SEQ ID NO: 3 or NO: 4; DNA fragment comprising a partial sequence of the cDNA; recombinant vector having the cDNA; antibody against human H37 protein; and a method for controlling the proliferation of cells by introducing the above DNA or antibody into the cells.Type: GrantFiled: November 1, 1999Date of Patent: May 24, 2005Assignee: Japan Science and Technology AgencyInventors: Kenichi Arai, Hisao Masai
-
Patent number: 6855685Abstract: The invention relates to an anti-cancer agent containing ?-chain protein (?-fragment) of HGF (hepatocyte growth factor) as an active ingredient. The active ingredient of ?-fragment has a specific suppressing effect on invasion and metastasis of cancer cells such as gallbladder cancer, lung cancer and other, which are highly metastatic and result in a high mortality. Therefore, the agent of the invention is used in treatment and prevention of cancer as an anti-cancer agent, and is extremely useful clinically.Type: GrantFiled: September 14, 2001Date of Patent: February 15, 2005Inventor: Toshikazu Nakamura
-
Patent number: 6849599Abstract: The invention provides antineoplastic composition containing an inhibitor of angiogenesis and an inhibitor of DNA topoisomerase type I enzyme activity.Type: GrantFiled: March 8, 2001Date of Patent: February 1, 2005Assignee: Rhode Island HospitalInventors: Paul Calabresi, James Darnowski
-
Patent number: 6828111Abstract: A three-dimensional in vitro culture system comprising breast epithelial cells, endothelial cells and breast fibroblasts supports growth and functional differentiation of preneoplastic breast epithelial cells and endothelial cells and recapitulates estrogen induced in vivo effects on angiogenesis and proliferative potential of breast epithelial tissue. This model permits the generation of functional vascular networks and local proliferative ductal alveolar outgrowths with invasive potential. Both these processes are augmented by estrogen. This culture model is used to evaluate agents for their effects, whether stimulatory or inhibitory, on preneoplastic breast disease and its progression to cancer.Type: GrantFiled: January 16, 2001Date of Patent: December 7, 2004Assignee: Wayne State UniversityInventors: Malathy P. V. Shekhar, Larry Tait
-
Patent number: 6824773Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: December 19, 2000Date of Patent: November 30, 2004Assignee: Immunex CorporationInventor: Steven R. Wiley
-
Patent number: 6821947Abstract: Angiogenesis is a highly regulated process, yet many diseases are driven by unregulated angiogenesis. For example, the growth and metastasis of tumors is dependent on the growth of new blood vessels, which nurture the tumor by providing not only a growth-conducive environment but also a route by which metastatic cells can escape. The present invention provides an angiogenesis inhibiting agent endorepellin, its fragments or derivatives, or analogs thereof, which inhibit angiogenesis. The invention disclosed herein provides a novel therapeutic approach to the treatment of tumors, and other angiogenesis-mediated diseases or conditions, by inhibiting the generation of new blood vessels. The present invention also provides anti-endorepellin, its fragments or derivatives, or analogs thereof, antibodies for the detection, diagnosis and monitoring of angiogenesis-mediated diseases or conditions.Type: GrantFiled: December 4, 2001Date of Patent: November 23, 2004Assignee: Thomas Jefferson UniversityInventor: Renato V. Iozzo
-
Patent number: 6805864Abstract: The present invention relates to a novel hybridoma cell line which secretes monoclonal antibodies capable of binding to the AT1 subtype of the Angiotensin II receptor. It also relates to monoclonal antibodies secreted by the hybridoma, which antibodies may be used in diagnostic test kits as well as having therapeutic applications.Type: GrantFiled: March 31, 2000Date of Patent: October 19, 2004Assignee: Queen Mary & Westfield CollegeInventors: Gavin Paul Vinson, Stewart Barker